➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: October 26, 2021

DrugPatentWatch Database Preview

Patent: 10,280,468

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

Summary for Patent: 10,280,468
Title:Molecular diagnostic test for predicting response to anti-angiogenic drugs and prognosis of cancer
Abstract: Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers.
Inventor(s): Harkin; Denis Paul (Dromore, GB), Kennedy; Richard (Belfast, GB), Keating; Katherine E. (Magherafelt, GB), McCavigan; Andrena (Derryadd Lurgan, GB), Hill; Laura A. (Lisburn, GB), Deharo; Steve (Belfast, GB), Davison; Timothy (Hillsborough, GB), Patterson; Fionnuala (Hauxton, GB), Donegan; Sinead (Belfast, GB), Jellema; Gera (Portadown, GB), Gourley; Charlie (Dumfermline, GB)
Assignee: Almac Diagnostics Limited (Craigavon, GB)
Application Number:15/116,641
Patent Claims:see list of patent claims

Details for Patent 10,280,468

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. AVASTIN bevacizumab Injection 125085 2004-02-26 ⤷  Free Forever Trial 2034-05-28
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.